Aclarion Completes First Nociscan Exams in Norwegian LIFEHAB Trial
TL;DR
Aclarion's Nociscan technology provides an advantage in identifying chronic low back pain biomarkers for treatment response.
Nociscan uses Magnetic Resonance Spectroscopy to quantify biomarkers and proprietary algorithms to determine the source of pain.
Nociscan's potential to help physicians identify optimal treatment options could improve patient outcomes and reduce chronic low back pain.
Aclarion's Nociscan technology is an innovative approach using magnetic resonance spectroscopy for noninvasive disc pain evaluation.
Found this article helpful?
Share it with your network and spread the knowledge!
Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company specializing in biomarkers and augmented intelligence algorithms, has announced the completion of the first Nociscan exams for patients in the LIFEHAB trial in Norway. This randomized controlled trial is evaluating the effectiveness of lumbar interbody fusion surgery versus multidisciplinary rehabilitation in treating chronic low back pain in 202 patients.
The LIFEHAB trial aims to determine how magnetic resonance spectroscopy (MRS) biomarkers can identify patient improvement following treatment. Patient enrollment began in the second quarter of 2024, and the first six patients have completed their Nociscan exams as of the last week of August.
Brent Ness, Aclarion CEO, expressed enthusiasm about the trial's progress, stating, "We are excited to see the LIFEHAB Trial progressing on schedule and look forward to the results of the study and to the role we expect Nociscan data to play in not only helping physicians determine which discs to treat but in potentially helping to predict which treatment option is optimal for a particular patient."
Nociscan technology is also being evaluated in Rome for its role in regenerative technologies and in two NIH studies focused on chronic low back pain. Ryan Bond, Aclarion's Chief Strategy Officer, noted, "We see Nociscan moving at an accelerated pace of adoption in the research market and look forward to announcing more partnerships as we continue to drive Nociscan to what we expect to be the gold standard for determining which discs to treat in research protocols on low back pain."
The findings from the LIFEHAB trial, combined with other studies, could be instrumental in achieving successful reimbursement within national health insurance systems like Norway's. Aclarion believes the trial marks a significant step toward broader adoption of Nociscan in both clinical and research settings, potentially setting a new standard for diagnosing and treating chronic low back pain.
LIFEHAB joins other customer-sponsored clinical trials involving Nociscan, and Aclarion is optimistic about future partnerships and the continued expansion of Nociscan's research market presence.
For more information on the LIFEHAB Trial, visit https://classic.clinicaltrials.gov/ct2/show/NCT06169488.
Curated from NewMediaWire
